Rockefeller Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Rockefeller Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$221K	Hold	71,666	–	–	﹤0.01%	2439
2025 Q4	$108K	Buy	71,666 +35,000	+95%	+$83.2K	﹤0.01%	2683
2025 Q3	$95K	Buy	+36,666	New	+$107K	﹤0.01%	2599
2023 Q1	–	Sell	-1,666	Closed	-$3K	–	2521
2022 Q4	$3K	Hold	1,666	–	–	﹤0.01%	3453
2022 Q3	$4K	Hold	1,666	–	–	﹤0.01%	3391
2022 Q2	$4K	Hold	1,666	–	–	﹤0.01%	3535
2022 Q1	$6K	Hold	1,666	–	–	﹤0.01%	3270
2021 Q4	$7K	Hold	1,666	–	–	﹤0.01%	3135
2021 Q3	$10K	Hold	1,666	–	–	﹤0.01%	2885
2021 Q2	$13K	Hold	1,666	–	–	﹤0.01%	2662
2021 Q1	$17K	Hold	1,666	–	–	﹤0.01%	2345
2020 Q4	$25K	Sell	1,666 -1	-0.1%	-$19	﹤0.01%	1912
2020 Q3	$28K	Hold	1,667	–	–	﹤0.01%	1675
2020 Q2	$14K	Hold	1,667	–	–	﹤0.01%	1785
2020 Q1	$12K	Buy	+1,667	New	+$15.9K	﹤0.01%	1678

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Rockefeller Capital Management's ELDN Position: Q1 2026 in Review

Rockefeller Capital Management held its Eledon Pharmaceuticals (ELDN) position steady in Q1 2026 at 71,666 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #2439.

Rockefeller Capital Management first reported a position in ELDN in Q1 2020 and has held it in 15 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

Rockefeller Capital Management held 71,666 shares of Eledon Pharmaceuticals worth $221K as of Q1 2026.
Rockefeller Capital Management left its Eledon Pharmaceuticals share count unchanged in Q1 2026.
Eledon Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #2439 holding.
Rockefeller Capital Management first reported a position in Eledon Pharmaceuticals in Q1 2020 and has held it in 15 quarters since.
121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.